Amoxicillin/clavulanic acid

From Infogalactic: the planetary knowledge core
(Redirected from Co-amoxiclav)
Jump to: navigation, search
Amoxicillin/clavulanic acid
File:Co-amoxiclav2DCSD.svg
Combination of
Amoxicillin Penicillin antibiotic
Clavulanic acid Beta-lactamase inhibitor
Clinical data
Trade names Augmentin, Clavamox, Tyclav, other
AHFS/Drugs.com monograph
MedlinePlus a685024
Licence data US FDA:link
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration		 oral, intravenous
Identifiers
CAS Number 74469-00-4 N
ATC code J01CR02 (WHO)
PubChem CID: 6435923
ChemSpider 4940608 YesY
ChEMBL CHEMBL1697738 N
 NYesY (what is this?)  (verify)

Amoxicillin/clavulanic acid (INN) or co-amoxiclav (BAN) is an antibiotic useful for the treatment of a number of bacterial infections. It is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. This combination results in an antibiotic with an increased spectrum of action and restored efficacy against amoxicillin-resistant bacteria that produce β-lactamase.

Side effects include an increased risk of yeast infections and diarrhea.[1]

It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.[2] Amoxicillin/clavulanic acid was developed at Beecham Pharmaceuticals and marketed under the trade name Augmentin.[3] It is available as a generic and marketed under a variety of trade names worldwide.

Medical uses

Amoxicillin/clavulanic acid is widely used to treat or prevent many infections caused by susceptible bacteria, such as:

Adverse effects

Possible side effects include diarrhea, vomiting, nausea, thrush, and skin rash. These do not usually require medical attention. As with all antimicrobial agents, antibiotic-associated diarrhea due to Clostridium difficile infection—sometimes leading to pseudomembranous colitis—may occur during or after treatment with amoxicillin/clavulanic acid.[4]

Rarely, cholestatic jaundice (also referred to as cholestatic hepatitis, a form of liver toxicity) has been associated with amoxicillin/clavulanic acid. The reaction may occur up to several weeks after treatment has stopped, and usually takes weeks to resolve. It is more frequent in men, older people, and those who have taken long courses of treatment; the estimated overall incidence is one in 100,000 exposures.[4] In the United Kingdom, co-amoxiclav carries a warning from the Committee on Safety of Medicines to this effect.[3]

As all aminopenicillins, amoxicillin has been associated with Stevens–Johnson syndrome/toxic epidermal necrolysis, although these reactions are very rare.[4][5]

History

British scientists working at Beecham (now part of GlaxoSmithKline), filed for US patent protection for the drug combination in 1979.

A patent was granted in 1985.[6]

Augmentin is the original name used by its inventor.

Preparations

Many branded products indicate their strengths as the quantity of amoxicillin. Augmentin 250, for example, contains 250 mg of amoxicillin and 125 mg of clavulanic acid.[3][7]

An intravenous preparation has been available in the UK since 1985,[8] but no parenteral preparation is available in the US; the nearest equivalent is ampicillin/sulbactam.

Suspensions of amoxicillin/clavulanic acid are available for use in children. They must be refrigerated to maintain effectiveness.

Veterinary use

Amoxicillin/clavulanic acid is used in numerous animals for a variety of conditions.

Dogs: periodontitis, kennel cough[9][10]

Cats: urinary tract infections,skin and soft tissue infections

Calves: enteritis, navel ill

Cattle:respiratory tract infections, soft tissue infections, metritis, mastitis

Pigs:respiratory tract infections, colibacillosis, mastitis, metritis, agalactia

In combination with prednisolone, it is used for intramammary infusion for the treatment of mastitis in lactating cows. Trade names include Clavaseptin, Clavamox, and Synulox.

Amoxicillin/clavulanic acid is banned from use in domestic-food animals (cattle, swine, etc.) in both the US and Europe; in the UK, Synulox can be used in domestic-food animals as long as a specified withdrawal period is observed.

Bacterial resistance

Bacterial antibiotic resistance is a growing problem in veterinary medicine. Amoxicillin/clavulanic acid is reported to be effective against clinical Klebsiella infections, but is not efficacious against Pseudomonas infections.[11]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ 3.0 3.1 3.2 3.3 Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ 4.0 4.1 4.2 4.3 Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ US 4441609 
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  9. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  10. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  11. ↑ Federation of Veterinarians in Europe Position Paper: Antibiotic Resistance & Prudent Use of Antibiotics in Veterinary Medicine

External links

Retrieved from "https://infogalactic.com/w/index.php?title=Amoxicillin/clavulanic_acid&oldid=2295362"